340B Drug Pricing Program Contributes to Rising Healthcare Costs and Is Ripe for Reform
The U.S. House Energy & Commerce Committee's Health Subcommittee today will host the third hearing in its health care affordability series, specifically examining the role providers and hospitals play in shaping the cost of care for Americans.
While the hearing will likely examine numerous issues, there is none more ripe for reform than the flawed 340B drug pricing program.
Originally enacted to help eligible safety-net providers buy medicines at steep discounts and pass the savings on to lower-income and vulnerable patients, the program has ballooned as a revenue stream for many participating hospitals and contract pharmacy chains.
As the size and complexity of the 340B program has expanded, participating hospitals and contract pharmacies have instead used the program to increase…[more]
Although recent improvements in the Middle East naturally cast renewed focus on the Nobel committee’s marquee Peace Prize, the organization also deserves credit for its choice in this year’s Prize in Economic Sciences.
This year’s trio of winners – Joel Mokyr, Philippe Aghion and Peter Howitt – were notable “for having explained innovation-driven economic growth,” in the Nobel committee’s words.
More specifically, the trio’s scholarship in innovation-driven growth highlights underappreciated role of intellectual property…
